Plasma ACE2 species are differentially altered in COVID-19 patients
Studies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enz...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad Miguel Hernández de Elche |
| Repositorio: | REDIUMH. Depósito Digital de la UMH |
| OAI Identifier: | oai:dspace.umh.es:11000/31134 |
| Acceso en línea: | https://hdl.handle.net/11000/31134 |
| Access Level: | acceso abierto |
| Palabra clave: | ACE2 biomarker COVID- 19 plasma SARS- CoV- 2 CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología |
| id |
ES_0d1edfeba4589e1f466efd2f8e75ac8e |
|---|---|
| oai_identifier_str |
oai:dspace.umh.es:11000/31134 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Plasma ACE2 species are differentially altered in COVID-19 patientsGarcía Ayllón, María SaludMoreno Pérez, ÓscarGarcía Arriaza, JuanRamos Rincón, José ManuelCortés Gómez, María ÁngelesBrinkmalm, GunnarAndrés, MarianoLeón Ramírez, José ManuelBoix Martínez, VicenteGil, JoanZetterberg, HenrikEsteban, MarianoMerino de Lucas, EsperanzaACE2biomarkerCOVID- 19plasmaSARS- CoV- 2CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. OncologíaStudies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination.Wiley [Commercial Publisher]Instituto de NeurocienciasDepartamentos de la UMH::Medicina Clínica202420242021info:eu-repo/semantics/articleapplication/pdf16application/pdfhttps://hdl.handle.net/11000/31134reponame:REDIUMH. Depósito Digital de la UMHinstname:Universidad Miguel Hernández de ElcheIngléshttps://doi.org/10.1096/fj.202100051Rinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/oai:dspace.umh.es:11000/311342026-05-27T13:36:21Z |
| dc.title.none.fl_str_mv |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| title |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| spellingShingle |
Plasma ACE2 species are differentially altered in COVID-19 patients García Ayllón, María Salud ACE2 biomarker COVID- 19 plasma SARS- CoV- 2 CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología |
| title_short |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| title_full |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| title_fullStr |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| title_full_unstemmed |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| title_sort |
Plasma ACE2 species are differentially altered in COVID-19 patients |
| dc.creator.none.fl_str_mv |
García Ayllón, María Salud Moreno Pérez, Óscar García Arriaza, Juan Ramos Rincón, José Manuel Cortés Gómez, María Ángeles Brinkmalm, Gunnar Andrés, Mariano León Ramírez, José Manuel Boix Martínez, Vicente Gil, Joan Zetterberg, Henrik Esteban, Mariano Merino de Lucas, Esperanza |
| author |
García Ayllón, María Salud |
| author_facet |
García Ayllón, María Salud Moreno Pérez, Óscar García Arriaza, Juan Ramos Rincón, José Manuel Cortés Gómez, María Ángeles Brinkmalm, Gunnar Andrés, Mariano León Ramírez, José Manuel Boix Martínez, Vicente Gil, Joan Zetterberg, Henrik Esteban, Mariano Merino de Lucas, Esperanza |
| author_role |
author |
| author2 |
Moreno Pérez, Óscar García Arriaza, Juan Ramos Rincón, José Manuel Cortés Gómez, María Ángeles Brinkmalm, Gunnar Andrés, Mariano León Ramírez, José Manuel Boix Martínez, Vicente Gil, Joan Zetterberg, Henrik Esteban, Mariano Merino de Lucas, Esperanza |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Instituto de Neurociencias Departamentos de la UMH::Medicina Clínica |
| dc.subject.none.fl_str_mv |
ACE2 biomarker COVID- 19 plasma SARS- CoV- 2 CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología |
| topic |
ACE2 biomarker COVID- 19 plasma SARS- CoV- 2 CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología |
| description |
Studies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2024 2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/11000/31134 |
| url |
https://hdl.handle.net/11000/31134 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
https://doi.org/10.1096/fj.202100051R |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf 16 application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley [Commercial Publisher] |
| publisher.none.fl_str_mv |
Wiley [Commercial Publisher] |
| dc.source.none.fl_str_mv |
reponame:REDIUMH. Depósito Digital de la UMH instname:Universidad Miguel Hernández de Elche |
| instname_str |
Universidad Miguel Hernández de Elche |
| reponame_str |
REDIUMH. Depósito Digital de la UMH |
| collection |
REDIUMH. Depósito Digital de la UMH |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403322055655424 |
| score |
15.301603 |